WO2026142604 - SUSTAINED-RELEASE FAMPRIDINE TABLET WITH HIGH FLOWABILITY AND MOISTURE CONTROL
National phase entry is expected:
Publication Number
WO/2026/142604
Publication Date
02.07.2026
International Application No.
PCT/TR2025/051377
International Filing Date
03.11.2025
Title **
[English]
SUSTAINED-RELEASE FAMPRIDINE TABLET WITH HIGH FLOWABILITY AND MOISTURE CONTROL
[French]
COMPRIMÉ DE FAMPRIDINE À LIBÉRATION PROLONGÉE À HAUTE FLUIDITÉ ET CONTRÔLE DE L'HUMIDITÉ
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
SUNEL, Fatih
ATAK, Fadime Bilgehan
IPEK, Celaleddin
PEHLIVAN AKALIN, Nur
ULUSOY BOZYEL, Muge
YENI, Songul
DAGCIOGLU, Erdal
Priority Data
2024/020491
25.12.2024
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2029 | |
| EPO | Filing, Examination, Granting | 8986 | |
| Japan | Filing, Examination, Granting | 2122 | |
| South Korea | Filing, Examination, Granting | 1987 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,864
Contact Us
Abstract[English]
The present invention relates to a sustained-release fampridine composition with high flowability and moisture control which can be used to treat individuals affected with multiple sclerosis and a preparation process thereof.[French]
La présente invention concerne une composition de fampridine à libération prolongée à haute fluidité et contrôle de l'humidité pouvant être utilisée pour traiter des individus atteints de sclérose en plaques, ainsi qu'un procédé de préparation de celle-ci.